Rate of Immunological Failure and Its Predictors among Patients on Highly Active Antiretroviral Therapy at Debremarkos Hospital, Northwest Ethiopia by ALEMU, YAYEHIRAD
INSTITUTE OF PUBLIC HEALTH
COLLEGE OF MEDICINE AND HEALTH SCIENCE
UNIVERSITY OF GONDAR
Rate of Immunological Failure and Its Predictors among Patients 
on Highly Active Antiretroviral Therapy at Debremarkos Hospital, 
Northwest Ethiopia
By: YAYEHIRAD ALEMU (BSc.)
Name of advisors
1. TADESSE AWOKE (MSc in Statistics, MSc in Biostatistics)
2. MAMO WUBSHET (MSc, PhD candidate)
A  THESIS SUBMITTED TO THE INSTITUTE OF PUBLIC HEALTH, COLLEGE 
OF MEDICINE AND HEATLH SCIENCES, UNIVERSITY OF GONDAR IN 
PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF 
MASTTER OF PUBLIC HEALTH IN EPIDEMIOLOGY AND BIOSTATISTICS.
June, 2012
Gondar, Ethiopia
INSTITUTE OF PUBLIC HEALTH
COLLEGE OF MEDICINE AND HEALTH SCIENCE
UNIVERSITY OF GONDAR
Rate of Immunological Failure and Its Predictors among Patients 
on Highly Active Antiretroviral Treatment at Debremarkos 
Hospital, Northwest Ethiopia
BY: YAYEHIRAD ALEMU (BSc.)
                                             Tel: +251-913-25-08-04
                                         Email: 078yayu@gmail.com      
                                
Approved by the Examining Board
---------------------------------------------------                  ---------------------------------
ADVISORS
3. TADESSE AWOKE       --------------------------------------------
4. MAMO WUBSHET       ----------------------------------------------
-----------------------------------------                              ---------------------------------------
Examiner
iACKNOWLEDGEMENT
I would like to forward my heartfelt gratitude to my advisors Mr. Tadesse Awoke 
and Mr. Mamo Wubshet for their kindhearted encouragement and constructive 
comments starting from the very beginning of developing the research proposal
to this final work. My advisors make me confident enough to conduct the study. I 
would like also to thank Debremarkos hospital administration and staffs for giving 
permission and facilitating the data collection. 
My deepest thankfulness will also goes to my friends especially to G/Selassie 
Demeke for logistic support and providing constructive comments for the 
betterment of this research report.
My grandmother, Emahoy Zewditu Tegegne, deserves my wholehearted 
appreciation for teaching me to be me.
ii
Contents
ACKNOWLEDGEMENT ........................................................................................ i
LIST OF TABLES..................................................................................................iv
LIST OF FIGURES ............................................................................................... v
ABBREVIATIONS AND ACRONYMS...................................................................vi
ABSTRACT..........................................................................................................vii
1. INTRODUCTION............................................................................................ 1
1.1. STATEMENT OF THE PROBLEM .......................................................... 1
1.2. LITERATURE REVIEW ........................................................................... 3
ANTIRETROVIRAL TREATMENT FAILURE........................................ 31.2.1.
FACTORS ASSOCIATED WITH ART FAILURE............................... 41.2.2.
1.3. JUSTIFICATION OF THE STUDY........................................................... 7
2. OBJECTIVE ................................................................................................... 8
3. METHODS ..................................................................................................... 9
3.1. STUDY DESIGN AND PERIOD............................................................... 9
3.2. STUDY AREA.......................................................................................... 9
3.3. POPULATION.......................................................................................... 9
Source Population ............................................................................. 93.3.1.
Study population ............................................................................... 93.3.2.
Inclusion and Exclusion Criteria ...................................................... 103.3.3.
3.4. SAMPLE SIZE AND SAMPLING TECHNIQUE ..................................... 10
3.5. VARIABLES OF THE STUDY................................................................ 14
3.6. OPERATIONAL DEFINITIONS.............................................................. 15
3.7. DATA COLLECTION, QUALITY CONTROL AND ANALYSIS............... 15
Data collection procedure................................................................ 153.7.1.
Data Quality Control ........................................................................ 163.7.2.
Data Analysis .................................................................................. 163.7.3.
iii
3.8. ETHICAL CONSIDERATION................................................................. 17
4. RESULTS..................................................................................................... 18
4.1. Baseline Socio-Demographic Characteristics of the Study Participants 18
4.2. Clinical Characteristics of Patients at Initiation of ART .......................... 20
4.3. Immunological Failure after Initiation of Highly active Antiretroviral 
Treatment ........................................................................................................ 22
4.4. Predictors of Immunological Failure....................................................... 27
5. DISCUSSION............................................................................................... 32
6. LIMITATIONS............................................................................................... 35
7. CONCLUSIONS........................................................................................... 36
8. RECOMMENDATIONS ................................................................................ 37
9. REFERENCES............................................................................................. 38
ANNEX ............................................................................................................... 40
Annex 1: Data Collection Format..................................................................... 40
Annex 2- Information Sheet ............................................................................. 44
iv
LIST OF TABLES
Table 1 Sample size calculation with different proportions and predictors from two 
studies for determining rate and predictors of immunological failure at 
Debremarkos hospital, Northwest Ethiopia, 2012. --------------------------  11 
Table 2 Baseline Socio-demographic characteristics of HIV/AIDS patients on 
antiretroviral therapy at Debremarkos Hospital, Northwest Ethiopia, May 
2012. ------------------------------------------------------------------------------------  19
Table 3 Baseline Clinical characteristics of HIV/AIDS patients on antiretroviral 
therapy at Debremarkos Hospital, Northwest Ethiopia, May 2012. ------ 21
Table 4 The outcome status of the study subjects at the end of follow up with 
respect to their initial socio-demographic and clinical characteristics at 
Debremarkos Hospital, Northwest Ethiopia, May 2012. -------------------- 26
Table 5 The Cox-Regression output for predictors of immunological failure among 
patients taking ART at Debremarkos Hospital, Northwest Ethiopia, May 
2012. ------------------------------------------------------------------------------------ 31
vLIST OF FIGURES
Figure 1 Conceptual framework of immunological failure and its predictors among 
HIV positive patients on ART. -------------------------------------------------------- 6
Figure 2 Schematic presentation of sampling procedure from HIV/AIDS patients on 
ART at Debremarkos hospital, Northwest Ethiopia, May 2012. ----------- 13
Figure 3 Past Opportunistic infection status of HIV/AIDS patients on antiretroviral 
therapy at Debremarkos hospital, Northwest Ethiopia, May, 2012.------- 20 
Figure 4 Pie-chart for length of follow up time of patients on ART at Debremarkos 
hospital, Northwest Ethiopia, May 2012. ---------------------------------------- 22  
Figure 5 Prevalence of immunological failure at different months of follow up of 
HIV/AIDS patients on antiretroviral therapy at Debremarkos hospital, 
Northwest Ethiopia, May 2012. ---------------------------------------------------- 23
Figure 6 Status of study participants at the last observation at Debremarkos 
hospital Northwest Ethiopia, May 2012. ----------------------------------------- 24
Figure 7 Kaplan Meir curve for immunological failure of HIV infected patients taking 
antiretroviral therapy at Debremarkos hospital, Northwest Ethiopia, May, 
2012.--------------------------------------------------------------------------------------  25
Figure 8 Kaplan Meir curve comparing immunological failure of HIV patients on 
ART according to Weight change at Debremarkos hospital, Northwest 
Ethiopia, May 2012. ------------------------------------------------------------------ 28
Figure 9 Kaplan Meir curve comparing immunological failure of HIV patients on 
ART according to Baseline CD4 count category at Debremarkos hospital, 
Northwest Ethiopia, May 2012.----------------------------------------------------- 29
vi
ABBREVIATIONS AND ACRONYMS
3TC Lamivudine
AHR Adjusted Hazard Ratio
AIDS Acquired Immune Deficiency Syndrome
ART Antiretroviral Therapy
ARV Antiretroviral Drug
AZT Zidovudine
d4t Stavudine
DDI Didanosine
E.C Ethiopian Calendar
EFV Efavirenz
G.C Gregorian Calendar
HAART Highly Active Anti- Retroviral Therapy
Hgb Hemoglobin
HIV Human Immunodeficiency Virus
HR Hazard Ratio
IQR Inter Quartile Range
NNRTI Non-nucleoside Reverse Transcriptase Inhibitor
NRTI Nucleoside analogue Reverse Transcriptase Inhibitor
NVP Nevirapine
OI Opportunistic Infection
TLC Total Lymphocyte Count
UNAIDS United Nations’ Program on HIV/AIDS
URTIs Upper Respiratory Tract Infections
VL Viral Load
WHO World Health Organization
vii
ABSTRACT 
Introduction: Since the mid-1990s, antiretroviral drugs have been effective in 
prolonging the life span of people infected with HIV.  Viral load monitoring is the 
gold standard to diagnose failure of antiretroviral treatment but it is not generally 
available in resource-limited settings. Thus in resource-limited settings patients 
on antiretroviral treatment monitored by using immunological and clinical follow 
up, this keep patients on a failing regimen.
Objective: To determine the rate and associated factors of Immunological failure 
among patients on highly active antiretroviral treatment (HAART) at Debremarkos
hospital, Northwest Ethiopia, May 2012. 
Methods: Retrospective longitudinal study was conducted on 509 adults who 
started HAART at Debremarkos hospital within a period of January 01, 2007 to 
April 01, 2008. Medical records of these patients were reviewed from ART start 
date up to April 01, 2012. The data were collected from clients ART chart using 
data extraction format by trained nurses. Data were entered in to Epi-Info 2002 
and exported into SPSS windows version 20 for analysis. Kaplan-Meier curve 
was used to estimate the time to event. Both bivariate and multivariate Cox 
proportional hazards models were used to identify predictors of immunological 
failure.
Result: The median age at initiation of treatment was 35 (IQR: 11) years and the 
median follow up time was 36 months (IQR=37 months). Among study 
participants 302 (59.3%) were females. At the end of follow up, 107(21%) had 
developed immunological failure. The rate of immunological failure after 63 
months on ART was 8 per 100 patient-years. Recurrent pneumonia infection
(AHR=1.623, 95%CI: 1.095, 2.404), unemployment (AHR: 1.741, 95%CI: 1.107, 
2.738), baseline CD4 count ≤100 cells/mm3 (AHR: 2.160, 95%CI: 1.435, 3.252) 
and No change or decrease in body weight (AHR: 4.335, 95%CI: 2.930, 3.229)
were significant predictors of immunological failure.
Conclusion and Recommendations: The immunological failure rate was higher
than other sub-Saharan Africa studies. It will be good to monitor patients who had 
higher risk of immunological failure with viral load monitoring not to let them on 
failing regimen.
Key Words: Antiretroviral therapy, Immunological failure, Survival analysis
11. INTRODUCTION 
1.1. STATEMENT OF THE PROBLEM
According to World Health Organization (WHO) statistics, globally there were  about 
34.0 million people living with HIV in 2010 (1).  Sub-Saharan Africa continues to bear 
an inordinate share of the global HIV burden there were about  23 million people 
living with HIV/AIDS in the region (2).  Ethiopia belongs to the heavily affected 
countries of Sub-Saharan Africa by HIV/AIDS, at a prevalence rate of 2.4%, an 
estimated of 1,216,908 people living with HIV/AIDS in 2010 (3).
Since the mid-1990s, antiretroviral drugs have been effective in prolonging the life 
span of people infected with HIV, transforming HIV from a fatal acute disease to a 
manageable chronic condition (4). According to Federal HIV/AIDS Prevention and 
Control Office at the beginning of February, 2010 Cumulative number of people ever 
started antiretroviral treatment (ART) in Ethiopia were 246,347 among these 232697 
were age >14 years (5).
Although, the primary goal of highly active antiretroviral treatment (HAART) is to 
suppress viral load below the level of detection within three to six months of starting 
therapy and to maintain it for the rest of the patient’s life, there are also other 
important goals of HAART including restoring and preserving immunologic function, 
reducing HIV-related morbidity and mortality, improving quality of life and reducing 
vertical transmission (6).
One challenge to antiretroviral treatment is the requirement of consistent use of the 
medication in order to reduce the possibility that the virus will adapt and become 
resistant to the drug. Finding feasible and affordable means for early detection of 
treatment failure is crucial to sustain first-line therapy effectiveness (4, 7). Viral load 
monitoring is the gold standard used in high-income countries to diagnose failure of 
ART, but it is not generally available in resource-limited settings because of its 
expensiveness (8).
2Therefore, taking resource constraints into account, and that virological failures 
precede immunological failures, then comes clinical failure, WHO guidelines 
recommend clinical and immunological (CD4+ count) assessments as surrogates for 
viral load to monitor patients on ART in resource limited settings (9). However, the 
sequential nature of treatment failure which is not strongly evidence based and may 
take years to happen (6).
Hence, diagnosing treatment failure based on the clinical or immunological criteria 
will lead keeping patients on a failing regimen which in turn leads to the reversal of 
clinical conditions of patients to the pre-treatment state, increase risk of mortality and 
development of drug resistant strains. It will be shocking if once drug resistant virus 
start transmission in the population (10, 11).
It would be best to look for ways of predicting treatment failure early.  Knowing 
factors associated with ART failure will help to identify those at higher risk of 
developing failure earlier so that appropriate measures will be taken during their 
follow up to try and avoid development of failure. With this information, clinicians 
could give such patients special attention during their follow-up and the limited 
resources available for diagnosing treatment failure can be used for them.
31.2. LITERATURE REVIEW
ANTIRETROVIRAL TREATMENT FAILURE1.2.1.
Antiretroviral treatment failure is associated with virologic failure, immunologic 
failure, and/or clinical failure. Virological failure is said to be occurred when Plasma 
viral load above 5000 copies/ml and Immunological Failure when there is Fall of 
CD4 count to baseline (or below) OR 50% fall from on-treatment peak value OR 
Persistent CD4 levels below 100 cells/mm3. Clinical failure is said to be occurred 
when new or recurrent WHO stage 4 conditions occurred (12).
A study done in a university hospital in Thailand had found in 6 years follow up the 
cumulative incidence was 33.5% for immunological failure (13). However, in 33 
months retrospective follow-up study in India, the cumulative incidence of treatment 
failure was low as 3.9% (14).
A six year retrospective follow up study conducted in South Africa where adults on 
ART were stratified by age at initiation found that 16.6% of patients had poor 
immunological response with the largest proportion being in those aged 50 years 
and above (11). Another retrospective cohort study in rural South Africa showed 
13% prevalence of immunological failure (15), this value was slightly higher in a 
Tanzanian cross-sectional study which found 17.1% prevalence of immunological 
failure (16). 
A retrospective follow up study conducted in rural Uganda shown that 
immunological failure was 7.9% at month 12 and 38% at month 24 (17). In 36-
month follow up study in HIV-1 infected women in Côte d’Ivoire the overall 
probability of immunological failure was 0.08 at 12 months, 0.14 at 24 months and 
0.21 at 36 month (18).  A retrospective cohort study in Soweto, South Africa 
demonstrated an overall immunologic failure rate of 27% by month 48 (7).
A systematic review conducted in resource limited settings by WHO found that 
failure rate per 100 patient years of follow-up (PYFU) in Africa was 2.64 using 
clinical/immunological definitions of treatment failure (19).
4FACTORS ASSOCIATED WITH ART FAILURE 1.2.2.
Socio-demographic 
A study conducted in rural Uganda has shown that ≥35 years of age at ART start 
was associated with virologic failure [OR=2.3] (21) and the Asia Pacific HIV 
Observational Database study found that lower CD4 cell count responses were 
found to be associated with increasing age (22). However, a prospective cohort 
study in South Africa found that treatment failure was higher in adolescents 
compared to young adults where incidence rate of treatment failure was 8.2 per 100 
person years among adolescents (9-19 years) while it was 5.0 per 100 person years 
among young adults (20-28 years) (23). Similarly study conducted in Canada using 
retrospective data shown that viral rebound was independently associated with 
being younger in age (24)
Indian retrospective study found that patients from urban areas had 1.9 times 
greater hazard for treatment failure compared with those from rural areas (14).
A retrospective observational cohort study in rural South Africa, male gender (OR 
1.7) significantly associated with treatment failure and immunologic failure (7, 25) .  
A study in India also show that men had a 3.5 times greater risk of treatment failure 
(14). However, these findings contradict with a study conducted in Canada (24).
Low education level was also found to be associated with immunologic failure (7).
Adherence 
A study in Thailand found that virological failure was strongly associated with 
adherence of <95% (13), while in China <100% adherence was associated with 
virologic failure in 6-11 month follow up cohort (26). A study conducted in Uganda 
has also shown that poor adherence was associated with virologic failure [OR=3.9] 
(17).  The risk of immunologic failure was 41% versus 19% among those with 
incomplete and complete adherence respectively after 48 months on ART (7).
Adherence below 95% was strongly associated with immunological treatment failure
(16). 
5CD4 count  
A study in Thailand found baseline CD4 count <100cells/mm3 and slow CD4 cell 
recovery of <50cells/mm3 after 6 months of HAART to be predictors of 
immunological failure (13).  A retrospective study at Massachusetts General 
Hospital has shown Treatment Failure  was significantly associated with absolute 
neutrophil count <1000 cells/mm3 (HR= 2.90) and baseline CD4 count <200 
cells/mm3 (HR = 1.90) (25).
In contrast higher mean CD4 cell counts were associated with lower baseline CD4 
cell count and consistently undetectable viral loads (22, 27). Similarly, there was 
significant association between baseline CD4 of more than 100cell/ μl and 
immunological treatment failure in a study conducted in Tanzania (16).
Regimen
In a retrospective study, compared to other regimens, the percentage of treatment 
failure was significantly greater in the regimens that included efavirenz (14).  In
contrast a study conducted in Uganda patients treated with d4T/3TC/NVP were 2.6 
times more likely to develop virologic failure than patients treated with ZDV/3TC/EFV 
(7). In contrast to this in a retrospective observational cohort study in rural South 
Africa, Zidovudine-use associated with treatment failure (27).
Patients who had negative changes in, hemoglobin concentration and body weight 
had 3.2 and 3.5 times significantly greater risk of treatment failure respectively than 
patients in whom there was a positive change (14).
There are studies conducted in different parts of the world to identify predictors of 
immunologic failure. But this information is scarce in Ethiopia especially no study 
has been conducted at Debremarkos Hospital. Hence, this study will fill this gap. 
6Fig 1: Conceptual framework of immunological failure and its predictors among HIV 
positive patients on ART.
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71.3. JUSTIFICATION OF THE STUDY
Antiretroviral treatment failure will lead development of drug resistant virus unless it 
is detected early. This study will identify factors which will be used to predict 
immunological failure of treatment for the patient with those factors. If the time of 
failure is predicted the patient will get appropriate follow up and switched to second 
line ART without delay. Thus development of drug resistant virus which will occur 
due to keeping patients on failing regimen will be avoided.
In Ethiopia, patients on ART are monitored with immunological and clinical 
assessment, thus absence of viral load monitoring will let patients on failing regimen. 
By determining rate of immunological failure and identifying factors associated with 
it, the study will provide information for clinicians to use in the follow-up and 
management of patients on highly active antiretroviral treatment (HAART).  Public 
health professionals will also use the findings in the design of ART related programs 
and care and support activities.
The study will also give baseline information for further studies that will be conducted 
on the problem in the study area and other similar settings.
82. OBJECTIVE
2.1. General Objective
 To assess rate of immunological failure and its predictors among patients on
highly active antiretroviral treatment at Debremarkos Hospital, North West
Ethiopia, 2012. 
2.2. Specific Objectives
 To determine rate of immunological failure among patients on HAART at 
Debremarkos Hospital.
 To identify predictors of immunological failure among patients on HAART at 
Debremarkos Hospital.
93. METHODS
.
3.1. STUDY DESIGN AND PERIOD
A retrospective longitudinal study was conducted in April 2012.
3.2. STUDY AREA 
The study was conducted at Debremarkos Hospital which was established in 1964.  
The hospital is 300 km northwest of the capital Addis Ababa and 265 km southeast 
away from the Amhara regional city BahirDar. It serves for 3.5 million catchment 
population and has a total of 137 beds. 
The free based ART service was started on September 30, 2005. Totally there are 
8042 clients on HIV care service among these 4490 had ever started ART in the 
hospital. Currently there are 2611 clients taking their ART from the hospital. 
3.3. POPULATION
Source Population3.3.1.
The target population for this study includes all patients age ≥ 15 years with HIV 
infection and had ever started antiretroviral treatment in Northwest Ethiopia.
Study population 3.3.2.
All patients age ≥ 15 years with HIV infection and had ever started antiretroviral 
treatment at Debremarkos Hospital.
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Inclusion and Exclusion Criteria3.3.3.
Inclusion criteria
All patients with documented HIV infection who were under medical care at the ART 
Clinic and met the following criteria were included: 
 ≥ 15 years of age
 Started antiretroviral treatment within a period January 01, 2007 to April 01, 
2008.
 Had at least six months of follow up and 
Exclusion criteria
• Had missed baseline CD4 cell count and
• Had no at least one additional CD4 cell count after six month of ART follow 
up. 
3.4. SAMPLE SIZE AND SAMPLING TECHNIQUE
Sample size was computed for determining rate of immunological failure and for 
identifying its predictors. Since there was no study conducted in Ethiopia on 
immunological failure studies from other African countries were used in sample size 
calculation.
Single population proportion formula was used to compute sample size for 
determination of rate of immunological failure. A study conducted in rural Uganda 
had shown that immunological failure was 7.9% at month 12 and 38% at month 
24(17).
n= Z1-α/2 
2[p (1-p)] w2
Assuming; 
 a 0.05 level of significance, 
 Z1-α/2 will be 1.96 and 
 0.05 margin of error, w, the minimum sample size was computed using
each proportion.
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Sample size for identifying predictors was also calculated by using the predictor 
variables from study conducted at the Chris Hani Baragwanath Hospital, in the
Soweto town, South Africa (7) using EPI-INFO StatCalc software for 
cohort/comparative cross-sectional design. The following assumptions were 
considered for this calculation:
 Power = 85%
 Confidence level = 95%
 Ratio (number in exposed: non-exposed) = 1:1
Table 1: Sample size calculation with different proportions and predictors from two 
studies for determining rate and predictors of immunological failure at Debremarkos 
hospital, Northwest Ethiopia, 2012.
*P=proportion, OR=Odds Ratio
S.No. Variable Proportion sample 
size
1
Immunological failure at
12 month 0.079 112
24 month 0.38 362
          Assuming that 
proportion of
Immunological failure 
at some point during
follow up period
0.50 384
P*exposed P*unexposed OR*
2 Education
No or primary education 
(exposed)
Secondary or tertiary 
(unexposed)
8.0% 26.7% 0.34 218
3 Adherence
<95%(exposed)
95-100(unexposed)
34.6% 18.1% 2.39 246
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Accordingly, the minimum sample size was 384 and adding 10% for those patient 
charts with incomplete baseline variables the final sample size was 422.
There were 578 clients who started ART in the hospital within the period between 
January 01, 2007 and April 01, 2008 and fulfilled the inclusion and exclusion criteria. 
This time was chosen after assessment was conducted to find enough number of 
events and sample size.
Since it was logistically possible to include all 578 patients and good to increase the 
power of the study all 578 eligible patients were included in the study. 
Thus, all 578 patients who had started ART at Debremarkos hospital within the 
period between January 01, 2007 and April 01, 2008 and fulfilled the inclusion 
criteria were taken to be followed until April 01, 2012 with maximum follow up of 5 
years and 3 months.
13
Fig. 2: Schematic presentation of sampling procedure from HIV/AIDS patients on 
ART at Debremarkos hospital, Northwest Ethiopia, May 2012. 
1218 = start ART in a period January 01, 2007 to April 01, 
2008.
1195 = age ≥15 years
617 = didn't 
fulfill the 
inclusion 
criteria
578 =INCLUDED 
*had 6 months follow up and, 
*baseline and after 6 month CD4 
count
23 = <15 years
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3.5. VARIABLES OF THE STUDY
Dependent variable:
 Immunological failure and its time of occurrence
Independent variables:
 Socio-demographic variables
 Age
 Sex
 Marital Status
 Educational Status
 Religion 
 Residence 
 Base-line CD4 count
 WHO clinical stage at the baseline 
 Functional status 
 Type of regimens
 Drug Adherence
 Opportunistic infections at baseline 
 Nutritional variables at baseline and  changes during follow-up
 hemoglobin
 body weight
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3.6. OPERATIONAL DEFINITIONS
 Event: Occurrence of immunological failure
 Immunological Failure: Immunological failure said to be occurred 
when there is:
i. Fall of CD4 count to baseline (or below) OR 
ii. 50% fall from on-treatment peak value OR 
iii. Persistent CD4 levels below 100 cells/mm3 (12).
 Time to Immunological failure: Time from initiation of ART up to 
occurrence of immunological failure.
 Survival time: The time a patient waits without immunological failure.
 Censored:  Patients free of the event at the end of the study period or 
lost, died, transferred out or stop treatment before developing the event. 
For these patients, the data were censored at the date of the last visit.
3.7. DATA COLLECTION, QUALITY CONTROL AND ANALYSIS
Data collection procedure3.7.1.
Data were collected by three trained nurses.  Data collection format was used to 
extract all the necessary information from patient’s ART charts on the variables of 
interest. Pre-testing of the data collection format was done and modifications were
made on it. The medical records of patients who had started ART in the period 
between January 01, 2007 and April 01, 2008 were followed from the date of 
enrollment to April 01, 2012 using data extraction format for the occurrence of the 
event.  
The event was development of immunological failure.  Immunological failure was 
said to be occurred when there is fall of CD4 count to baseline (or below) or 50% fall 
from on-treatment peak value or persistent CD4 levels below 100cells/mm3.  
Patients free of the event at the end of the study period or lost, died, transferred out 
or stop treatment before developing the event were censored at the date of the last 
visit.
16
Data Quality Control3.7.2.
Pretesting was done on patient charts before the data collection was started to 
check the quality of the data extraction format and some modifications were made 
accordingly. One day training was given for three nurses who were working at the 
Art clinic of the hospital and daily supervision was done by the principal investigator.
Completed data extraction formats were checked daily for their completeness.
Data entry and cleaning was done by the principal investigator. 
Data Analysis3.7.3.
Data were first entered using Epi-Info 2002 and then analyzed using SPSS version 
20. Descriptive statistics was used to describe the study subjects and different 
variables. Kaplan–Meier survival analyses were used to estimate the time from 
initiation of antiretroviral therapy to immunologic failure.  Log rank test of equality of 
survival for the different categories of independent variables was also computed. 
Life table was computed to see the cumulative survival probability with six month 
time intervals. For patients who were not reached the endpoint, the data was 
censored at the date of the last visit. Bivariate and multivariate Cox-proportional 
hazard model was fitted to identify predictor variables of immunological failure. 
Variables with P<0.2 in a bivariate analysis were inserted into the multivariate 
analysis using Backward LR method. Hazard ratios and their 95% confidence 
intervals were computed. Variables with P-value of <0.05 were considered as 
significant predictors. The proportional hazards assumption was assessed with log-
log plots and regression of the Schoenfeld residuals. 
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3.8. ETHICAL CONSIDERATION
Ethical clearance was obtained from the Institutional Ethical Review Board of 
Institute of Public Health, Gondar University.  Permission letter was obtained from 
Debremarkos Hospital administration and ART coordinator. The names and ART 
unique numbers of patients were not used and confidentiality of information was kept 
by collecting data only by nurses who were working in the ART clinic. 
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4. RESULTS
4.1. Baseline Socio-Demographic Characteristics of the Study 
Participants
A total of 509 patients’ records were included in the analysis giving 88.1% of 
complete information. Of which 302 (59.3%) were females. The median age of 
patients at the start of ART was 35 (IQR= 11) years. From all study participants 
41.1% and 36.3% were in age the group of 25-34 and 35-44 (36.3%) years
respectively.
Most of patients 486 (95.5%) were Orthodox in their religion and married 200 
(39.3%) in marital status. Concerning educational status, 36.5% of the study 
participants were with no education, 481(94.5%) had disclosed their HIV status.
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Table 2: Baseline Socio-demographic characteristics of HIV/AIDS patients on 
antiretroviral therapy at Debremarkos Hospital, Northwest Ethiopia, May 2012. 
Variables Numbers %
Sex
       
Female 302 59.3
Male 207 40.7
Age (years)
15-24 54 10.6
25-34 209 41.1
35-44 185 36.3
45-54 49 9.6
55+ 12 2.4
Religion
Orthodox 486 95.5
Muslim 18 3.5
Protestant 5 1.0
Employment
Working full time 212 41.7
Unemployed 194 38.1
Not working due to ill health 57 11.2
Working part-time           46 9.0
Level of education
no education 186 36.5
Primary 144 28.3
Secondary 136 26.7
Tertiary 43 8.4
Residence
Urban 294 57.8
Rural 215 42.2
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4.2. Clinical Characteristics of Patients at Initiation of ART 
Almost all 493(96.9%) of patients had at least one opportunistic infection at the start 
of Antiretroviral therapy. 
                      Others = CMV, Herpes zoster, toxoplasmosis (brain), Extra-pulmonary TB
Fig. 3: Past Opportunistic infection status of HIV/AIDS patients on antiretroviral 
therapy at Debremarkos hospital, Northwest Ethiopia, May 2012.
Two hundred seventy five (54.0%) patients were working in their functional status 
and 78.2% of patients were having Hemoglobin measurement of ≥10mg/dl at the 
start of ART.  One hundred ninety five (38.3%) and 163 (32.0%) of patients had 
started treatment with Stavudine-Lamivudine- Nevirapine and Zidovudine-
Lamivudine-Nevirapine regimen respectively. 
Three hundred and eighteen (62.5%) of patients were eligible only by criteria of CD4 
count less than 200 cells/mm3 while 162(31.8%) were eligible by both CD4 bellow 
200 and  WHO stage II and III with total lymphocyte count (TLC) ≤1200.  From the 
total patients included in the study about 212(41.6%) had CD4 count ≤100cells/mm3
at antiretroviral initiation. The median baseline CD4 cell count was 117cells/mm3
(IQR=99).
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Table 3: Baseline Clinical characteristics of HIV/AIDS patients on antiretroviral 
therapy at Debremarkos Hospital, Northwest Ethiopia, May 2012.
Characteristics Number %
Eligibility criteria
Only CD4 below 200 318 62.5
Both CD4 below 200 and  WHO stage II and III with 
TLC≤1200
162 31.8
Both CD4 below 200 and WHO stage IV 22 4.3
WHO stage II and III with TLC<=1200 7 1.4
Functional status
Working 275 54.4
Ambulatory 222 44.0
Bedridden 8 1.6
WHO clinical stage
Stage I 1 0.2
Stage II 40 7.9
Stage III 451 88.8
Stage IV 16 3.1
Baseline CD4 count
≤100 cell/mm3 212 41.7
>100 cell/mm3 297 58.3
Drug type at initiation
d4t - 3TC- NVP 197 38.7
d4t - 3TC- EFV 97 19.1
AZT – 3TC- NVP 163 32.0
AZT – 3TC- EFV 52 10.2
Hemoglobin level
                      
                      
<10mg/dl 70 15.0
≥10mg/dl 398 85.0
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4.3. Immunological Failure after Initiation of Highly active 
Antiretroviral Treatment
Study participants were followed for a minimum of 6 months and maximum of 63 
months with median time of 36 months (IQR: 12.00 - 49.50 months). A total of 107 
(21%) patients found to have immunological failure after 63 months on ART. Based 
on the three criteria seated by WHO for defining immunological failure 62 (57.94%) 
were due to fall of CD4 counts to baseline or bellow while 44 (41.12%) were due to 
persistent CD4 counts bellow 100 cells/mm3. 
Fig. 4: Pie-chart for length of follow up time of patients on ART at Debremarkos 
hospital, Northwest Ethiopia, May 2012.   
Among overall prevalence of immunological failure 33(6.5%) were failed at 6 month 
of follow up while 62(12.2%), 84(16.5%), 89(17.5%), 97(19.0%) were failed at 12, 
18, 24 and 36 months of follow up respectively.
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Fig. 5: Prevalence of immunological failure at different months of follow up of 
HIV/AIDS patients on antiretroviral therapy at Debremarkos hospital, Northwest 
Ethiopia, May 2012.
Participants were followed for different period of time and the total person-time of 
follow up was 1334.42 patient-years of follow up. The rate of immunological failure 
after 63 months on ART was 8 per 100 patient-years.
The remaining 402(79%) patients were censored for different reasons: alive without 
failure until the end of study period, transferred out, lost, dropout out, or died before 
the end of the study period without developing the event. The percent for each 
reasons of censoring did not represent the prevalence of each out come since the 
study didn’t incorporate those with less than six months follow up on ART.
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Fig. 6: Status of study participants at the last observation at Debremarkos hospital 
Northwest Ethiopia, May 2012.
The mean survival time was 51.045 (95%CI: 49.046, 53.043) months. Life table had 
shown the cumulative probability of survival at 6, 12, 24, 36 and 60 month was 0.88, 
0.82, 0.79, 0.77 and 0.69 respectively.
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Fig. 7: Kaplan Meier curve for immunological failure of HIV infected patients taking 
antiretroviral therapy at Debremarkos hospital, Northwest Ethiopia, May 2012.
Fourty six (43.0%) and 41(38.3%) number of failure were seen in age group of 25-34 
years and 35-44 years respectively. According to employment status 42(40.7%) of 
the failure were seen among unemployed patients while 27(26.2%) failures were 
among patients who were not working due to ill health.
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Table 4: The outcome status of the study participants at the end of follow up with 
respect to baseline socio-demographic and clinical characteristics at Debremarkos 
Hospital, Northwest Ethiopia, May 2012.
Variables Immunological Failure Total
Yes No
Age
15-24 7(6.5%) 47(11.7%) 54(10.6%)
25-34 46(43.0%) 163(40.5%) 209(41.1%)
35-44 41(38.3%) 144(35.9%) 185(36.3%)
45+ 13(12.2%) 48(11.9%) 61(12%)
Sex
Male 53 (49.5%) 154 (38.3%) 207 (40.7%)
Female 54 (50.5%) 248(61.7%) 302 (59.3%)
Hemoglobin change*
Positive change 8(33.3%) 10(14.7%) 18(19.6%)
No change /decrease 16(66.7%) 58(85.3%) 74(80.4%)
Weight change*
Positive change 54(56.2%) 77(20.2%) 131(27.5%)
No change/decrease 42(43.8%) 304(79.8%) 346(72.5%)
Recurrent URTIs
Yes
36(33.6%) 182(45.3%)
218(42.8%)
No
71(66.4%) 220(54.7%)
291(57.2%)
Baseline CD4
≤100 cell/mm3
63(58.9%) 149 (37.1%)
212(41.7%)
>100 cell/mm3
44(41.1%) 253(62.9%)
297(58.3%)
*change = End value – initial value
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4.4. Predictors of Immunological Failure
In Log rank test for the different categories of independent variables; Recurrent 
Upper Respiratory Tract Infections (URTIs), Employment, baseline CD4 cell count
and Weight change were significantly associated with immunological failure. 
Log rank test for the two levels of Recurrent URTIs had shown a chi-square value of 
4.42 (p=0.036).  Accordingly there is significant difference in failure time of patients 
with and without Recurrent URTIs.
Log rank test of equality of failure time distributions for the two levels of Weight 
change had shown a significant chi-square value of 48.908 (P<0.001). Patients that 
show increase in their body weight from the baseline to the last observation had 
significantly different failure time compared to patients that show no change or 
decrease in their body weight. 
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Fig. 8: Kaplan Meier curve comparing immunological failure of HIV patients on ART 
according to Weight change at Debremarkos hospital, Northwest Ethiopia, May 
2012.
Log rank test for the two levels of baseline CD4 count had also shown significant 
difference in failure time between two levels of baseline CD4 counts with chi-square 
value of 16.902 (P<0.001). Therefore, there is a significant difference in failure time 
between patients with baseline CD4 ≤100cells/mm3 and patients with baseline CD4 
>100cells/mm3.
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Fig. 9: Kaplan Meier curve comparing immunological failure of HIV patients on ART 
according to Baseline CD4 count category at Debremarkos hospital, Northwest 
Ethiopia, May 2012.
Log rank test for the different categories of employment had shown a chi-square 
value of 7.919 (p=0.048) which indicates that failure time was significantly 
associated with employment status. 
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Cox-Regression Analysis
The bivariate Cox-proportional hazard model was fitted for all explanatory variables 
and five variables; recurrent URTIs, employment, baseline CD4 count, and weight 
change were found to be significantly associated with time to immunological failure.
All explanatory variables with p-value of ≤0.2 were inserted in the multivariate Cox-
regression to see the independent effect each variable on immunological failure. 
Sex, Recurrent URTIs, Pneumonia (recurrent), Employment, Baseline CD4 count
and Weight change were the six explanatory variables fitted in the multivariate Cox-
proportional hazard model with Backward LR method of analysis. Backward LR 
method was used to get the most parsimonious model by controlling multi co-
linearity.  The variables recurrent pneumonia infection, employment status, baseline 
CD4 count and weight change were found to be significantly associated with time to 
immunological failure in the multivariate analysis.
Accordingly, those patients with recurrent pneumonia infection at the baseline were 
1.62 times at higher risk of immunological failure compared to those patients without 
recurrent pneumonia [AHR= 1.623, 95%CI: 1.095, 2.404].
Employment status was found to be significantly associated with immunological 
failure.  Unemployed patients had 1.74 times higher hazard of immunological failure 
compared to those patients who were working full time [AHR= 1.741, 95%CI: 1.107, 
2.738]. Similarly patients who were not working due to ill health had 2.19 times 
greater risk of immunological failure compared to full time worker patients at the start 
of ART [AHR= 2.19, 95%CI: 1.195, 4.015].
Baseline CD4 cell count was also significantly associated with immunological failure.
Those patients with baseline CD4 count ≤100cells/mm3 were 2.16 times more likely 
to have immunological failure at any time compared  to those patients with CD4 
count greater than 100cells/mm3 [AHR= 2.160, 95%CI: 1.435, 3.252]. 
Weight change was also significant predictor of immunological failure. Accordingly 
those having had no change or decrease in their body weight had 4.34 times higher 
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hazard of immunological failure compared to those patients with positive change 
[AHR= 4.335, 95%CI: 2.930, 6.414].
Table 5: The Cox-Regression output for predictors of immunological failure among 
patients taking ART at Debremarkos Hospital, Northwest Ethiopia, May 2012.
Variable Immunological 
Status
Crude HR [95% CI] Adjusted HR [95% 
CI]
Failed Censored
Recurrent 
Pneumonia
Yes 63 263 1.39 [0.94, 2.04] 1.62[1.09, 2.40]*
No 44 139 1 1
Recurrent URTIs
Yes 36 182 1.52 [1.02, 2.28]*
No 71 220 1
Employment
Working full time           32 180 1 1
Working part 
time
10 36 1.58[0.78, 3.21] 1.58[0.77, 3.23]
Not working due 
to ill health
17 40 2.12[1.18, 3.82]* 2.19[1.20, 4.02]*
Unemployed 48 146 1.62[1.03, 2.53]* 1.74[1.11, 2.74]*
Weight Change
Positive  48 323 1 1
No/negative 59 79 3.53[2.41, 5.16]* 4.34 [2.93, 3.23]*
Sex
Male 53 154 1.19[0.98, 1.44]
Female 54 248 1
Baseline CD4 
≤100cells/m3 63 149 2.18[1.48, 3.20]* 2.16 [1.44, 3.25]*
>100cells/m3 44 253 1
*found significant at 0.05 level significance
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5. DISCUSSION
Diagnosing treatment failure based on the clinical or immunological criteria will lead 
keeping patients on a failing regimen which in turn leads to the reversal of clinical 
conditions of patients to the pre-treatment state, increase risk of mortality and 
development of drug resistant strains. It will be shocking if once drug resistant virus 
start transmission in the population (10,11). This study was aimed at finding the 
predictors of immunological failure after start of first line antiretroviral drugs so that 
clinicians and other health care providers can predict the probability that a patient 
will develop immunological failure. This information will help in avoiding delay to 
switch the patient to second line regimen. 
At the end of the 63 months follow up, 107 (21%) patients had developed 
immunological failure. This is higher than retrospective studies done in South Africa
13% (15) and Tanzania 17% (16) of immunological failure.  This can be due to 
shorter follow up time of these two studies which were 48 and 29 months of follow 
up respectively. Similarly a retrospective cohort study with median follow up time of 
44 months conducted Soweto, South Africa demonstrated an overall immunologic 
failure rate of 19% by month 99 (7) which was also lower even if the follow up time
was longer than the current study which had a median follow up time of 36 months. 
This lower prevalence might be due to smaller sample size of 456 this study 
compared to 509 study subjects of the current study and socio-economic 
differences.
Among all prevalence of immunological failure 33(6.5%) were failed at 6 month of 
follow up while 62(12.2%), 84(16.5%), 89(17.5%), 97(19.0%) were failed at 12, 18, 
24 and 36 months of follow up respectively. The result of this study underscore 
important feature of patients on ART that is high early immunological failure more 
than half of the 63 month prevalence were seen in the first 12 months follow up. 
This high early immunological failure might reflect the advanced stage of the disease 
at the start of the treatment due to different immunosuppressive opportunistic 
infections.
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The rate of immunological failure after 63 months on ART was 8 per 100 patient-
years of follow up. A systematic review conducted in in Africa found that failure rate 
per 100 patient years of follow-up was 2.64 in which failure was defined by using 
clinical/immunological definitions of treatment failure (19). This finding is much lower 
than the finding of the current study, this might be due to the reason that the current 
study uses only immunological criteria to define treatment failure. It might also be 
due to the socio-economic difference between those patients included in the 
systematic review and the current study subjects.
According to the multivariate Cox regression analysis patients with recurrent 
pneumonia infection at the initiation of ART were 1.62 times higher at risk of 
immunological failure compared to those patients without recurrent pneumonia 
keeping other variables constant. Thus it can be explained as those patients who 
suffer from recurrent pneumonia at the start of ART might be more 
immunosuppressed.
Employment status was also significantly associated with immunological failure. 
Accordingly, unemployed patients had 1.74 times higher risk of immunological failure 
compared to those patients who were working full time. Similarly patients who were 
not working due to ill health had 2.19 times greater risk of immunological failure 
compared to full time working patients at the start of ART. This might be due to the 
reason that those who work full time may have better income to get better care 
including diet than unemployed so that they will have better immunological 
response. Those patients unable to work due to ill health were also at higher risk of 
immunological failure compared to working patients, this can be due to the reason 
that not working patients were at advanced stage of the disease and greater 
immunosuppression and also can be due to loss of income due to being unable to 
work. So that, not working patients may have poor immunological response.
Baseline CD4 cell count was the other variable which had shown a significant
association with immunological failure. Those patients with baseline CD4 count 
≤100cells/mm3 were 2.16 times more likely to have immunological failure at any time 
compared  to those patients with baseline CD4 count greater than 100cells/mm3. 
This association was also seen in a study conducted in Thailand which also found 
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low baseline CD4 as predictor of immunological failure (13). Similarly in a 
retrospective study conducted in South Africa found that patients initiating ART with 
a CD4 cell count of >100 cells/ml had a significantly higher median CD4 cell count in 
comparison to patients started on ART at a CD4 cell count of ≤100 cells/ml 
throughout the follow-up period (7).
This can be due to the reason that patients with lower baseline CD4 count are more 
immunosuppressed than those patients with higher CD4 count so that they will fail to 
have increased CD4 response while patients with ≥100cells/mm3 are better to have 
increased CD4 response on treatment follow up. Lower baseline CD4 count 
indicates more advanced stage of HIV/AIDS.
In contrast a study done in Tanzania found that immunological failure was 
significantly associated with baseline CD4 count of more than 100cells/μl (16). This 
might be explained as those patients with higher baseline CD4 might have higher 
probability to be failed by the criteria of fall CD4 count to baseline or bellow even if 
that failing count might be higher than those patients with low baseline CD4.
Weight change also had shown strong association with immunological failure.
Accordingly, those patients having had no change or decrease in their last body 
weight from the baseline had 4.34 times higher hazard of immunological failure 
compared to those patients with positive change. This finding was similar to the 
finding of a study done in India in which patients who had negative changes in body 
weight had 3.5 times significantly greater risk of immunological failure than patients 
in whom there was a positive change (14). This can be explained as, an increase in 
body weight may indicate better diet and better health this in turn may be due to 
improvement of immunity including increase in CD4 cells.
Drug adherence was not significant predictor of immunological failure in the current 
study while poor adherence was found to be significant predictor of treatment failure 
in other studies(7, 17). This might be due to the reason that adherence was 
measured only by patients self-report in our study. Mostly patients tell what the care 
giver desire, so they report as they were good adherents.
Hemoglobin measurement was not used in the analysis because of high number of 
missing values.  This might be due to the reason that clinicians and care givers may 
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not take it as an important for following and managing patients. But in a study 
conducted in India found that patients who had negative changes in hemoglobin 
concentration had 3.2 times greater risk of immunological failure than patients in 
whom there was a positive change (14).
6. LIMITATIONS 
Being retrospective limits the study to find out more predictors than those recorded 
in the charts. 
Data incompleteness especially for follow up variables was also the other limitation 
which made difficulty to see clinical responses of patients since the data was 
collected from secondary source.
The other limitation of this study was that since failure was only measured by 
immunological criteria it may not assure the presence of treatment failure. 
There were patients who were on follow up but had no CD4 count for more than 6 
month gap from previous count. Misclassification bias might be occurred in these 
patients who had missed the CD4 measurement on time. 
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7. CONCLUSIONS
 The immunological failure rate was higher compared with other studies 
conducted in sub-Sahara African countries. 
 There was high early immunological failure, more than half of immunological 
failures occurred during the first 12 months of ART initiation.
 The independent predictors of immunological failure were; having had 
recurrent pneumonia infection, being unemployed, being unable to work due 
to ill health, low baseline CD4 count and no change or decrease in body 
weight.
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8. RECOMMENDATIONS
To Hospitals and Health care providers managing Patients on ART
 Viral load monitoring for patients who are at higher risk of immunological
failure not to let them on a failing regimen.
 Continue follow up of patients with regular body weight measurement to 
early detect treatment failure.
 Shall improve regular hemoglobin measurement and recording.
 Strengthening and continuing in informing patients about the need for early 
diagnosis of HIV infection and timely start of ART before further 
immunosuppression had occurred. Since it is important to decrease the risk 
of immunological failure.
To governmental and non-governmental organizations 
 Shall strengthen and continue in finding strategy to help and support 
unemployed patients in increasing their income.
To researchers
 Further Studies with prospective follow up design shall be planned to find out
additional predictors of immunological failure. 
 Recurrent pneumonia was found to be independent predictor of 
immunological failure; this finding needs more study on pathophysiology 
recurrent pneumonia and its association with lower CD4 response. 
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ANNEX
Annex 1: Data Collection Format
Data Extraction Format
This questionnaire is prepared for the collection of socio-demographic, clinical, 
treatment and immunological related information that are important for the 
assessment of immunological failure and associated factors. All this information will 
be retrieved from the clients ART and pre-ART registration book/chart without 
mentioning the name of client. This information will be collected by the nurses who 
are currently working in the ART clinic of the Debremarkos hospital.   
Contact Information              
1. Yayehirad Alemu (Principal Investigator)         Tel: +251-913-250804  
2. Ato Tadesse Awoke (Advisor)                         Tel: +251-910-173308
3. Ato Mamo Wubshet (Advisor)                          Tel: +251-912-180307
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  Part I: Socio-demographic Characteristics
Circle the letter of choice and say Data Not Available (DNA) when there was 
missed data.
ART Unique ID No.: _____________                patient Card No.:__________
s.no. Variable Description/category
1 Age (years) at initiation
Sex 1. Male                                 2. Female
2 Marital-Status 1. Never married         4. Divorced                                
2. Married                    5. Widowed
3. Separated          
3 Level of Education 1. No education                                      
2. Primary
4. Secondary                               5. Tertiary
4 Patient address 1. Woreda _______________
2. Kebele ______________
5 Religion 1. Muslim          3. Catholic
2. Orthodox      4. Protestant 
5.other ______
6 Employment 1. Working full time           3. Not working 
2. Working part-time          4. Unemployed
7 Disclosure status 1. Disclosed
2. Not disclosed
8 Addictions (Substance 
abuse) 
1. Tobacco                       3.Soft drugs 
2. Alcohol                         4. Hard drugs  
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Part II: Antiretroviral Treatment
s.no. Variable Description/category
1 past Opportunistic Illness 1. Candidiasis 
2. Oropharyngeal candidiasis
3. Diarrhea (>1 month)
4. Kaposi Sarcoma
5. Recurrent pneumonia
6. Pneumocystis Carinii pneumonia 
7. Toxoplasmosis
8. Others/specify______
2 OI prophylaxis  1. Cotrimoozole
2. INH
3. Fluconazol
4. None  
3 Eligibility criteria 1. Immunological/CD4 below 200
2. WHO stage IV
3. Both 
4 Date ART
started 
______/_______/_______ (E.C)               
5 Regimen 1. 1a(30) =d4t (30) - 3TC - NVP 
2. 1a(40) =d4t (40) - 3TC - NVP  
3. 1b(30) =d4t (30)- 3TC- EFV       
4. 1b(40) =d4t (40)- 3TC- EFV       
5. 1c = AZT-3TC-NVP
6. 1d = AZT-3TC-EFV
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Part III: follow up values of selected criteria
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Patient’s status at last visit
1. Date of last visit       ______/_______/_______ (E.C)               
2. Status 
1. Alive                          3.Transferred out
2. Dropout                     4. Died 
Questionnaire filled and completed by Approved by
Name ___________ Name ___________ 
Signature ___________ Signature ________
Date___________ Date__________
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Annex 2- Information Sheet 
Title of the Research Project: Immunological Failure and Associated Factors 
among patients on antiretroviral treatment at Debremarkos Hospital, North West
Ethiopia.     
Name of Principal Investigator:  Yayehirad Alemu
Name of the Organization: University of Gondar, College Of Medicine and Health 
Sciences.
Name of the Sponsor: University of Gondar
Introduction: This information sheet is prepared for Debremarkos Hospital 
administration and hospital ART program coordinating office. The aim of the form is 
to make the above concerned offices clear about the purpose of research work, data 
collection procedures and get permission to undertake the research. 
Purpose of the Research Project: To assess antiretroviral treatment failure and 
associated factors in patients taking ART at Debremarkos Hospital, North West
Ethiopia.  
Procedure: In order to achieve the above objective, sample of patients will be taken 
from all HIV infected adults and who are on ART in the hospital. 
Risk and /or Discomfort: By participating in this research project, there is totally no 
risk that comes to one whom document is reviewed whereas the review is of great 
importance to the research project; which is in turn important for overall planning of 
the ART program.
Benefits:  The research have no direct benefit for one whose document/record is 
included in this research. But the indirect benefit of the research for the participant 
and all other clients in the program is clear. This is because if program planners 
prepare plan for the program based on the result of this study clients in the program 
will benefit by getting appropriate care and treatment services.
Of all, the research work has a paramount direct benefit for health care planners and 
managers, especially for those on ART program planning and management. 
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Confidentiality: To keep the confidentiality of the records of the clients, the record 
will be extracted by ART clinic staff nurses. Then, nurse data collectors will review 
the selected charts. The information collected from this research project will be kept 
strictly confidential and information reviewed about the clients by this study will be 
stored in a file, without name i.e. investigator uses number codes to the record 
during the review. The information gathered will not be accessible to anyone except 
the principal investigator and will be kept locked with password and appropriate 
locks.
Person to contact: This research project will be reviewed and approved by the 
institutional review board of college of medicine and health sciences, University of 
Gondar. If in case you want to know more information about the research and its 
undertakings, you can contact the committee through the address of the advisor 
and/or the principal investigator below. 
1. Ato Tadesse Awoke (BSc Statistics, MSc Biostatistics), University of Gondar, 
college of medicine and health sciences, Institute of public health: Advisor 
    Tel: +251-910-173308                 e-mail: t_awoke@yahoo.com
2. Ato Mamo Wubshet (MSc., PhD candidate): Gondar University, college of 
medicine and health sciences, Institute of public health: Advisor
     Tel: +251-912-180307            e-mail: Mamo_wubshet@yahoo.com
3. Yayehirad Alemu: Gondar University, College of Medicine and Health Science, 
Institute of Public Health: Principal Investigator                                                        
Cell phone: +251- 09 13 25 08 04    E-mail: 078yayu@gmail.com  
Permission: You are kindly requested to permit and forward your permission to 
concerned body in your organization so that the researchers can get cooperation 
from the data clerks and other responsible bodies in place.
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የመረጃና የስምምነት ውል ቅፅ
የምርምሩ/ጥናቱ ርዕስ:-
በደበረማረቆስ ሆሰፒታል የፀረ-ኤች አይ ቪ መድሃኒት የሚጠቀሙ አዋቂዎች መድሃኒት መዉሰድ ከጀመሩ በኋላ
የሚፈጠረዉን የህክምና አለመሳካት እና  ተዛመጅ ምክንያቶችን በተመለከተ ፡፡
የዋና ተመራማሪው ስም፡     ያየህራድ ዓለሙ
የድርጅቱ ስም:  በጎንደር ዩኒቨርሲቲ ህክምናና ጤና ሳይንስ ኮሌጅ የህብረተሰብ ጤና አጠባበቅ ኢነሰቲቲዩት
ወጪውን የሚሸፍነው አካል፡  ጎንደር ዩኒቨርሲቲ
መግቢያ:
ይህ የመረጃና የስምምነት ውል ቅፅ የተዘጋጀው ለ ደበረማረቆስ ሆሰፒታል አስተዳደር አንዲሁም በሆሰፒታሉ ለሚገኘዉ
የፀረ-ኤች አይ ቪ ህክምና አሰተባባሪ ነዉ፡፡  ዋና ዓላማዉም ስለ ምርምሩ ዓላማ፣ ስለ መረጃ አሰባሰቡ እንዲሁም
ጥናቱን ለማካሄድ ፈቃድ ለማግኘት ከላይ የተገለፁትን አካላት ግልፅ እንዲሆንላቸዉ ለማድረግ ነዉ፡፡
የጥናት ፕሮጀክቱ የሚካሄድበት ምክንያት :
የጥናቱ ዓላማ በ ደበረማረቆስ ሆሰፒታል የፀረ-ኤች አይ ቪ መድሃኒት የሚጠቀሙ አዋቂዎች መድሃኒት መዉሰድ
ከጀመሩ በኋላ የሚፈጠረዉን የህክምና አለመሳካት እና  ተዛመጅ ምክንያቶችን ለማጥናት ታቅዶ የተዘጋጀ ነዉ ፡፡
የጥናቱ ግኝት ችግሩን ለመፍታ በተለይም ደግሞ ጥናቱ በሚካሄድበት ቦታ ትክክለኛ የሆነ የመፍትሄ አቅጣጫ ለመቅረፅ
እንደመነሻ መሠረት ያገለግላል፡፡
አተገባበር:
የጥናቱን አላማ ለማሳከት በ ደበረማረቆስ ሆሰፒታል የፀረ-ኤች አይ ቪ መድሃኒት ከሚጠቀሙ አዋቂዎች ናሙና
ይዎስዳል፡፡  መረጃዉም የሚሰበሰበዉ ሙሉ በሙሉ በቻርት ላይ የተመሰረተ ነዉ፡፡
ሊገጥም የሚችል ችግር/አለመመቸት
በዚህ ጥናት ላይ ቻርታቸዉ የሚታይባቸዉ አዋቂዎች ምንም የሚደርስባቸዉ ጉዳት የለም፡፡ ነገር ግን መረጀቸዉ
ለጥናቱ በጣም አስፈላጊ ነዉ፡፡
ጥቅሞች:
በዚህ ጥናት ተሳታፊ የሚሆኑት የፀረ-ኤች አይ ቪ ህክምና ተከታታዮች በቀጥታ ሊያገኙት የሚችሉት ጥቅም ባይኖርም  
መረጃቸዉ  ግን የፀረ-ኤች አይ ቪ መድሃኒት የሚጠቀሙ ህፃናት መድሃኒት ከጀመሩ በኋላ ያላቸዉን የህክምና ክትትል
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አለመሳካት እንዲሁም  ተዛመጅ ክንያቶችን ለማጥናት ይጠቅማል፡፡  ቀጥተኛ ባልሆነ መልኩም ቢሆን የፀረ-ኤች አይ ቪ
ህክምና ተከታታዮች ተጠቃሚ ይሆናሉ፡፡
ምስጢራዊነት:
ለዚህ ጥናት የሚሰበሰበውን መረጃ ምስጢር ለመጠበቅ ሲባል መረጃዉ የሚሰበሰበዉ በሆሰፒታሉ ዉስጥ  በሚገኘዉ
የፀረ-ኤች አይ ቪ መድሃኒት መስጫ ክሊኒክ በሚሰሩ ነርሶች ነዉ፡፡ ከዚያ በኃላ የተመረጡት ነርሶች የፀረ-ኤች አይ ቪ
ህክምና ተከታታዮች ቻርት ላይ የሚገኘዉን መረጃ በሙሉ ይሰበስባሉ፡፡ የተሰበሰበዉ መረጃም ከጥናቱ ዋና ተመራማሪ
እና ረዳቶቹ በስተቀር ለሌላ ለማንኛዉም አይነት ሰዉ ግልፅ አይሆንም፡፡
ሊገናኙዋቸዉ የሚችሉ ሰዎች
ይህ የምርምር ፕሮጀክት በጎንደር ዩኒቨርስቲ የስነ ምግባር ኮሚቴ ተከልሶ የሚፀድቅ ይሆናል፡፡ የበለጠ መረጃ ማግኘት
የሚፈልጉ ከሆነ ኮሚቴዉን በሚከተሉት አድራሻ ማግኘት የችላሉ፡፡ የትኛዉም ዓይነት ጥያቄ ቢኖርዎት ከዘህ ቀጥሎ
የተጠቀሱትን ግለሰቦች ማግኘትና በማንኛዉም ጊዜ መጠየቅ የችላሉ፡፡
1. አቶ ታደሰ አወቀ :-ጎንደር ዩኒቨርስቲ፣ የህክምናና ጤና ሳይንስ ኮሌጅ፣ የህብረተሰብ ጤና አጠባበቅ
ኢንስቲቲዩት፡ የጥናቱ አማካሪ
       የሞባይል ስልክ ቁጥር: +251-910-173308   ኢ-ሜል: t_awoke@yahoo.com
2. አቶ ማሞ ዉብሸት፡- ጎንደር ዩኒቨርስቲ፣ የህክምናና ጤና ሳይንስ ኮሌጅ፣ የህብረተሰብ ጤና አጠባበቅ
ኢንስቲቲዩት፡ የጥናቱ አማካሪ
        የሞባይል ስልክ ቁጥር: +251-912-180307    ኢ-ሜል: Mamo_wubshet@yahoo.com
3. ያየህራድ ዓለሙ፡- ጎንደር ዩኒቨርስቲ፣ የህክምናና ጤና ሳይንስ ኮሌጅ፣ የህብረተሰብ ጤና አጠባበቅ
ኢንስቲቲዩት፡ ዋና ተመራማሪ
የሞባይል ስልክ ቁጥር: +251-913-250804      ኢ-ሜል: 078yayu@gmail.com
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I, the undersigned, senior MPH student declare that this thesis is my original work in 
partial fulfillment of the requirement for the degree of Master of Public Health in 
Epidemiology and Biostatistics.
Name: _________________
Signature: ______________
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